Nail psoriasis: a combined treatment with 8% clobetasol nail lacquer and tacalcitol ointment
|
|
- Sharon Burke
- 8 years ago
- Views:
Transcription
1 JEADV ISSN Blackwell Publishing Ltd ORIGINAL ARTICLE Nail psoriasis: a combined treatment with 8% clobetasol nail lacquer and tacalcitol ointment M Sánchez Regaña, G Márquez Balbás, P Umbert Millet Psoriasis and Phototherapy Center, Department of Dermatology, Hospital Universitari Sagrat Cor. Teaching Unit, University of Barcelona, Barcelona, Spain Keywords clobetasol, nail lacquer, nail psoriasis, nail, psoriasis, tacalcitol Correspondence: M. Sánchez Regaña. Department of Dermatology. Hospital Universitari Sagrat Cor. C/Paris th floor Barcelona, Spain, tel ; fax ; ez.reg@terra.es Received: 1 September 2007, accepted 20 December 2007 DOI: /j x Introduction Abstract Background Nail involvement is a common and distressing feature in the course of psoriasis. Although much progress has been made in the treatment of the disease, the presence of psoriasis in the nail continues to pose a challenge. In recent years, vitamin D3 analogs and a new formulation containing 8% clobetasol-17-propionate in a colourless nail lacquer vehicle have produced good results for the control of nail psoriasis. Objective To determine the efficacy and safety of the combined treatment of 8% clobetasol-17-propionate in a lacquer vehicle and tacalcitol ointment in nail psoriasis. Methods Fifteen patients with both nail bed and nail matrix psoriasis were included in the study. They were treated with a colourless nail lacquer containing 8% clobetasol-17-propionate applied at bedtime at the weekend, and with tacalcitol ointment under occlusion on the remaining days, for 6 months. Results All 15 patients responded well to treatment. The therapeutic effect was very fast and directly related to the length of therapy. All nail alterations, including nail pain, were reduced, and the modified target Nail Psoriasis Severity Index fell by an average of 78% compared to baseline levels (±59.6, P < ). Conclusions Combined treatment with tacalcitol ointment and 8% clobetasol- 17-propionate in a nail lacquer is a safe, effective treatment for nail bed and nail matrix psoriasis. Psoriasis is a common skin disorder that may affect the nails. Indeed, nail involvement is a common feature and is found in between 10% and 78% of patients; 1 of the 164 psoriatic patients in a previous study by our group, 53% had nail lesions. 2 Fingernails are more affected than toenails. Nail psoriasis is strongly associated with psoriatic arthritis and also with scalp psoriasis; it is rare in children. In the study by De Jong et al. (n = 1728), 51.8% of patients suffered from nail pain, and 58.9% of these reported a severe impact on their quality of life. 1 A recent study indicated a striking divergence of psoriasis severity depending on the presence or absence of HLA-Cw0602 (on chromosome 6). All types of nail lesions were prevalent in HLA-Cw0606-negative patients, whereas in HLA-Cw0602-positive patients, nail lesions correlated with psoriatic arthritis. 3 The clinical features of nail psoriasis are related to the portion of the nail unit affected by the disease. Nail matrix psoriasis is characterized by pitting, leukonychia, red spots in the lunula and occasionally by nail crumbling. Nail bed psoriasis shows onycholysis, salmon patch, splinter haemorrhages and nail bed hyperkeratosis. These features should be borne in mind in the selection of the treatment. Nail psoriasis is usually diagnosed by clinical findings; only rarely is performance of an ungual biopsy required. Recently, we and others have shown an above-average 2008 The Authors 963
2 Nail psoriasis: clobetasol 8% plus tacalcitol Regaña et al. prevalence of onychomycosis in patients with psoriasis. 4,5 In view of these results, it is mandatory to rule out concurrent mycosis when we are evaluating nail psoriasis patients prior to treatment. In recent years, the Nail Psoriasis Severity Index (NAPSI) has established itself as a reproducible, objective numerical tool for the evaluation of nail psoriasis. 7 Nevertheless, some authors have proposed a modified version of this scale for the evaluation of a target nail. 8 Finally, the scoring system proposed by Baran 9 evaluates several signs of nail psoriasis separately. Although the treatment of nail psoriasis has generally been considered unsatisfactory by patients and dermatologists, we believe that these new therapeutic options are extremely promising. To date, tests with topical treatments (for instance, topical and intralesional steroids and 1% 5- flurouracil) have produced poor results and are associated with major side effects such as pain, atrophy and discoloration. However, promising results have been reported in recent years with four topical treatments for nail psoriasis: calcipotriol, 8% clobetasol nail lacquer, topical cyclosporin and tazarotene. The therapeutic potential of calcipotriol ointment in occlusion has been tested in several studies that have also produced positive results. In our open study, patients completed 3 months of treatment and presented good response in all ungual lesions (especially onycholysis and subungual hyperkeratosis), with the exception of nail pitting. In a controlled study, Tosti et al. 11 showed that calcipotriol was as effective as a combination of betamethasone dipropionate and salicylic acid. Another series of 24 cases 12 confirmed that calcipotriol was particularly effective for treating subungual hyperkeratosis, onycholysis and discoloration when applied twice daily without occlusion for 3 months. In all these studies, calcipotriol proved to be safe and well tolerated, and we believe that this molecule has great potential in the treatment of nail psoriasis. However, with the exception of a single case report of a patient with nail psoriasis treated with calcitriol, 13 no data on other vitamin D3 analogs are currently available. To our knowledge, no studies of the effectiveness of tacalcitol ointment in nail psoriasis have been published to date. In 1999, Baran and Tosti 14 reported a major breakthrough in nail psoriasis treatment, using a new formulation containing 8% clobetasol-17-propionate in a colourless nail lacquer vehicle. Patients were divided into two groups: A and B. Group A patients (n = 26) were treated with the nail lacquer once daily until the end of treatment (average 2.5 months), whereas group B patients (n = 15) applied the nail lacquer once daily during the first week and two or three times per week from the second week onwards (average time, 7 months). Sixty-nine per cent of group A patients and 80% of group B patients showed a clear improvement after therapy. The signs that responded best to therapy were onycholysis and pitting, indicating action on the nail matrix. No side effects were reported. Later, our group performed an open study of 10 patients treated with 8% clobetasol nail lacquer 15 applied once daily for 21 days and then twice weekly for 9 months. Within 4 weeks of therapy, all nail alterations had improved, including nail pain. The response was directly related to the length of therapy. The nail parameters that responded best to therapy were onycholysis, pitting and salmon patches. However, subungual hyperkeratosis improved only moderately and splinter haemorrhages hardly at all. The treatment was well tolerated and highly acceptable from the cosmetic point of view; furthermore, no local and or systemic side effects were observed. In a recent prospective, randomized, placebo-controlled study, Cannavò et al. 16 reported the effectiveness of topical oil-dissolved 70% cyclosporin solution in nail psoriasis. In recent years, tazarotene has emerged as another promising option for this challenging form of psoriasis. Tazarotene s therapeutic potential has been evaluated in one open-label study 17 and in one placebo-controlled study 18 with good results. Rigopoulos et al. 19 conducted an interesting double-blind study comparing the efficacy of tazarotene 0.1% cream with clobetasol propionate 0.05% cream in nail psoriasis, concluding that tazarotene is a safe and effective therapy. Here, we report an open study conducted to evaluate the efficacy, tolerability and safety of a combination of a nail lacquer containing 8% clobetasol and tacalcitol ointment for the treatment of nail psoriasis. Patients and methods Patients Fifteen patients (6 men and 9 women, aged years) with nail psoriasis were included in the study. Informed consent was obtained from all subjects. The nail features of each patient at baseline are shown in Table 1. Inclusion criteria Involvement of the fingernail units (bed and matrix) with psoriasis resulting in any one of the following clinical findings: onycholysis, pitting, subungual hyperkeratosis, salmon patches, splinter haemorrhages and pain. Exclusion criteria Onychomycosis and bacterial infection were ruled out by direct microscopy (KOH) and cultures before and during the treatment. Other exclusion criteria were pregnancy or The Authors
3 Regaña et al. Nail psoriasis: clobetasol 8% plus tacalcitol Table 1 Clinical characteristics of our 15 patients at the beginning of the study n Sex (years) Age Type of psoriasis Subungual hyperkeratosis Onycholysis Salmon patches Splinter haemorrhages Pitting Pain NAPSI 1 M 40 Plaque-type M 56 Plaque-type M 34 Plaque-type F 65 Plaque-type M 58 Arthropathic F 48 Plaque-type M 53 Plaque-type F 79 Plaque-type F 71 Arthropathic F 62 Plaque-type M 44 Plaque-type F 53 Plaque-type F 33 Plaque-type F 31 Plaque-type F 49 Plaque-type M, male; F, female. +, mild; ++, moderate; +++, severe;, absent, 1 = yes; 2 = no. breast-feeding, age under 18, severe renal or hepatic insufficiency and intake of any systemic agent for psoriasis that might have affected the nail lesions during the past 6 weeks. Clinical assessment of efficacy All patients were evaluated at baseline, and after 3 and 6 months by the same dermatologist (Dr Sánchez Regaña). The severity of each nail psoriatic feature was scored from 0 (absent) to +++ (severe). An average of all nails involved was calculated. We also assessed the NAPSI at the same times using the modified target NAPSI for the target nail, as previously reported. 8 Briefly, the nail is divided into quadrants, and each quadrant is given a score of 0 to 3 to reflect zero, mild, moderate, or severe involvement for each parameter of nail matrix or bed psoriasis. The highest possible score is 96. Photographs were also taken, before and after treatment. Blood and urine cortisol and serum adrenocorticotropic hormone (ACTH) were assessed in all patients. Study design For 6 months, all patients applied tacalcitol monohydrate ointment 4 μg/g under occlusion five nights a week (Monday to Friday) and, at the week-end, a colourless nail lacquer containing 8% clobetasol-17-propionate, also at night. The nail lacquer was removed with a nail varnish remover before a new application, and nail occlusion was performed using cotton gloves. The times visits were 0, 12 and 24 weeks. fig. 1 Evolution of onycholysis during treatment. Statistical analysis The Wilcoxon signed ranks test was performed using the SPSS software (version 10.0; SPSS Inc, Chicago, IL), P < 0.05 was considered significant. Results All 15 patients showed good, progressive response to treatment. The results were noticeable after 4 weeks and were more marked at the end of treatment (6 months). All clinical signs of nail psoriasis showed a marked, maintained improvement (figs 1 10). Nail pain disappeared completely after 4 weeks in the 10 patients who had reported this symptom at baseline. At baseline, modified target NAPSI scores ranged from 8 to 49 (mean 20.87; ±10.41). At week 12, the modified 2008 The Authors 965
4 Nail psoriasis: clobetasol 8% plus tacalcitol Regaña et al. In the population under study, treatment with tacalcitol ointment five times a week, combined with 8% clobetasolfig. 2 Evolution of salmon patches during treatment. fig. 4 Evolution of subungual hyperkeratosis during treatment. fig. 3 Evolution of pitting during treatment. target NAPSI had fallen to a range of 0 to 26 (mean, 10.33; ±6.24), and finally at week 24 to a range of 0 to 11 (±3.33, P = 0.001; fig. 6). This represents a mean reduction of 78% from baseline levels (±59.6, P < ). The tolerability of both treatments (tacalcitol and nail lacquer) was excellent. None of the 15 patients presented atrophy at the end of the study. Repeated cultures fig. 5 Evolution of splinter haemorrhages during treatment. remained negative throughout. Laboratory tests (cortisol and ACTH) were also within normal ranges. Discussion fig. 6 Change in the modified target NAPSI during the study The Authors
5 Regaña et al. Nail psoriasis: clobetasol 8% plus tacalcitol fig. 7 Nail psoriasis with predominant onycholysis at the beginning of the study. fig. 8 Onycholysis after 12 weeks of treatment. 17-propionate in a colourless nail lacquer, effected a substantial improvement in all signs of nail psoriasis (both bed and matrix) at the end of the 6-month study. At week 24, all 15 patients presented improvement compared to baseline and achieved a mean reduction of 78% in the modified target NAPSI. These excellent results using 8% clobetasol nail lacquer in nail psoriasis have already been reported, by Baran and Tosti 14 and by our group. 15 The high concentration of clobetasol propionate (8%) did not cause skin atrophy or secondary infections in the present study and or in the two just mentioned. Furthermore, serum levels of cortisol and ACTH were within normal limits at the end of the study. In our previous study, 15 we observed that the parameters that responded best to therapy were onycholysis, pitting and salmon patches, whereas subungual hyperkeratosis and splinter haemorrhages presented moderate and poor improvement, fig. 9 Pitting before treatment. fig. 10 Pitting after 24 weeks of therapy. respectively. In the present study, all nail parameters showed a marked improvement, indicating a synergistic action between 8% clobetasol nail lacquer and tacalcitol. Clobetasol propionate and other topical steroids have been used in nail psoriasis for decades, but at the concentrations presently available on the market (0.05%), their control of the disease is poor because drug penetration is very limited. High concentrations (8%) and the lacquer vehicle optimize penetration. In contrast, intralesional injection of steroids may cause pain and atrophy. Recently, our group and others have reported the positive results obtained with calcipotriol in the treatment of nail psoriasis Another study has also shown the efficacy of calcitriol. 13 To date, tacalcitol has not been assessed. In this study, we used tacalcitol because it causes little irritation and also because only one application is needed The Authors 967
6 Nail psoriasis: clobetasol 8% plus tacalcitol Regaña et al. No standard therapeutic regimens exist for the use of topical steroids or vitamin D3 analogs in nail psoriasis. However, in clinical practice, physicians prescribe high potent steroids in occlusion when there is a predominance of nail matrix psoriasis. In nail bed psoriasis, an application of vitamin D3 can achieve optimal benefits. 21 Patients often present both nail bed and matrix psoriasis, and in this case, the combination of topical steroids and vitamin D3 analogs is synergistic. The good clinical results of this combination were observed by Rigopoulos et al. who used a combined treatment with calcipotriol cream and clobetasol cream. 22 We believe that the results obtained with this combination can be optimized by using a nail lacquer with a higher steroid concentration in order to increase the drug penetration into the nail. Although spontaneous remission in the course of nail psoriasis cannot be ruled out, we believe that the timing of the clinical responses observed in our study was suggestive of a synergistic effect of 8% clobetasol nail lacquer and tacalcitol ointment in the treatment of the disease. Although there is a strong evidence that cyclosporin 23 and biologics 6 are effective in nail psoriasis, in clinical practice, they are only rarely indicated when nail psoriasis is isolated. In conclusion, we believe that the combined treatment of 8% clobetasol nail lacquer and tacalcitol ointment is a safe, effective and cosmetically acceptable treatment for nail bed and matrix psoriasis. However, as our patient sample was small, further double-blind studies are necessary to confirm our results. Acknowledgement The authors are grateful to Dra Núria Parra for statistical analysis and Dra Teresa Serra Porta for her help with the figures. References 1 De Jong EMGJ, Seegers BA, Gulinck MK et al. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1728 patients. Dermatology 1996; 193: Sánchez Regaña M, Iglesias M, Creus L et al. Prevalencia de enfermedades hepáticas crónicas en pacientes con psoriasis. Actas Dermosifiliogr 2000; 91: Gudjonsson JE, Karason A, Runarsdottir EH et al. Distinct clinical differences between HAL-Cw*0602 positive and negative psoriasis patients an analysis of 1019 HLA-C- and HLA-B-typed patients. J Invest Dermatol 2006; 126: Sánchez Regaña M, Videla S, Villoria J et al. Report on the prevalence of fungal involvement in a series of patients with nail psoriasis. Clin Exp Dermatol 2007; 33: Gupta AK, Lynde CW, Jain HC et al. A higher prevalence of onychomycosis in psoriatics compared with nonpsoriatics: a multicentre study. Br J Dermatol 1997; 136: Lawry M. Biological therapy and nail psoriasis. Dermatologic Ther 2007; 20: Rich PH, Scher RK. Nail psoriasis severity index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003; 49: Parrish CA, Sobera JO, Elewski BE. Modification of the nail psoriasis severity index. J Am Acad Dermatol 2005; 53: Baran RL. A nail psoriasis severity index. Br J Dermatol 2004; 150: Sánchez Regaña M, Ojeda R, Umbert P. Empleo de calcipotriol tópico en la psoriasis ungueal. Piel 2002; 17: Tosti A, Piraccini BM, Cameli N et al. Calcipotriol ointment in nail psoriasis: a controlled double-blind comparison with betamethasone dipropionate and salicylic acid. Br J Dermatol 1998; 139: Zakeri M, Valikhani M, Mortazavi H, Barzegari M. Topical calcipotriol therapy in nail psoriasis: a study of 24 cases. Dermatol Online J 2005; 11: Usmani N, Wilson C. A case of nail psoriasis treated with topical calcitriol. Clin Exp Dermatol 2006; 31: Baran R, Tosti A. Topical treatment of nail psoriasis with a new corticoid-containing nail lacquer formulation. J Dermatol Treat 1999; 10: Sánchez Regaña M, Martin G, Umbert P. Treatment of nail psoriasis with 8% clobetasol nail lacquer: positive experience in 10 patients. J Eur Acad Derm Venereol 2005; 19: Cannavò SP, Guarneri F, Vaccaro M, Borgia F, Guarneri B. Treatment of psoriatic nails with topical cyclosporin: a prospective, randomized placebo-controlled study. Dermatology 2003; 206: Bianchi L, Soda R, Diluvio L, Chimenti S. Tazarotene 0.1% gel for psoriasis of the fingernails and toenails: an open prospective study. Br J Dermatol 2003; 149: Scher RK, Stiller M, Zhu YI. Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study. Cutis 2001; 68: Rigopoulos D, Gregoriou S, Katsambas A. Treatment of psoriatic nails with tazarotene cream 0.1% vs. Clobetasol propionate 0.05% cream: a double-blind study. Acta Derm Venereol 2007; 87: Lecha M, Mirada A, López S, Artes M. T.O.P. Research Group. Tacalcitol in treatment of psoriasis vulgaris: the Spanish experience. J Eur Acad Derm Venereol 2005; 19: The Authors
7 Regaña et al. Nail psoriasis: clobetasol 8% plus tacalcitol 21 Jiaravuthisan MM, Sasseville D, Vender RB et al. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 2007; 57: Rigopoulos D, Ioannides D, Prastitis N, Katsambas A. Nail psoriasis: a combined treatment using calcipotriol cream and clobetasol propionate cream. Acta Derm Venereol 2002; 82: Ojeda R, Sánchez Regaña M, Massana J, Oliete R, Umbert P. Clinical experience with the use of cyclosporin A in psoriasis. Results of a retrospective study. J Dermatol Treat 2005; 16: The Authors 969
L. Williamson, N. Dalbeth, J. L. Dockerty, B. C. Gee 1, R. Weatherall 2 and B. P. Wordsworth
Rheumatology ;:79 79 Advance Access publication 7 April Extended report: nail disease in psoriatic arthritis clinically important, potentially treatable and often overlooked L. Williamson, N. Dalbeth,
More informationReview Article. Review of nail psoriasis. Introduction. Impact of nail psoriasis. CT Chau
Hong Kong J. Dermatol. Venereol. (2015) 23, 13-19 Review Article Review of nail psoriasis Nail psoriasis is often an overlooked feature in the management of psoriasis. This review article explores the
More informationCLINICAL MANIFESTATIONS OF PSORIATIC NAIL AT THE NATIONAL HOSPITAL OF DERMATOLOGY AND VENEREOLOGY (NHDV)
Southeast-Asian J. of Sciences: Vol. 2, No 1 (2013) pp. 101-107 CLINICAL MANIFESTATIONS OF PSORIATIC NAIL AT THE NATIONAL HOSPITAL OF DERMATOLOGY AND VENEREOLOGY (NHDV) Nguyen Huu Sau and Nguyen Minh Thu
More informationNail psoriasis in Germany: epidemiology and burden of disease M. Augustin, K. Reich,* C. Blome, I. Schäfer, A. Laass and M.A.
EPIDEMIOLOGY AND HEALTH SERVICES RESEARCH BJD British Journal of Dermatology Nail psoriasis in Germany: epidemiology and burden of disease M. Augustin, K. Reich,* C. Blome, I. Schäfer, A. Laass and M.A.
More informationApproach to managing patients with nail psoriasis
DOI: 10.1111/j.1468-3083.2009.03364.x JEADV Blackwell Publishing Ltd REVIEW ARTICLE Approach to managing patients with nail psoriasis K Reich* Dermatologikum Hamburg, Hamburg, Germany *Correspondence:
More informationKey words: Psoriasis, Calcipotriol, Tazarotene. tazarotene. 16 ( 4 ) tazarotene calcipotriol ( 22 : 23-34, 2004)
In the treatment of plaque psoriasis, tazarotene was known to be effective, but its efficacy in a Taiwanese population has not been reported. Our purpose was to compare the efficacy, side effects and the
More informationFrequency and pattern of nail changes in patients with psoriasis vulgaris
Original Article Frequency and pattern of nail changes in patients with psoriasis vulgaris Ijaz Ahmed, Sarwat Nasreen Department of Dermatology, Ziauddin University Hospital, KDLB Campus, Karachi Abstract
More informationNail disorders. Prof. MUDr. Petr Arenberger, DrSc, MBA
Nail disorders Prof. MUDr. Petr Arenberger, DrSc, MBA Baseline Nail Disease in Patients with Moderate-to-Severe Psoriasis and Response to Treatment with Infliximab over One Year Phoebe Rich, Christopher
More informationNail Psoriasis. A positive approach. to psoriasis and. psoriatic arthritis
Nail Psoriasis A positive approach to psoriasis and psoriatic arthritis What is psoriasis? Psoriasis (Ps) is a long-term (chronic) scaling disease of the skin, which affects 2% 3% of the UK population.
More informationFastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. Please refer back to relevant sections
More informationEfficacy and Safety of Calcipotriol Ointment in Psoriasis Vulgaris - Experiences in Hong Kong
ORIGINAL ARTICLES Efficacy and Safety of Calcipotriol Ointment in Psoriasis Vulgaris - Experiences in Hong Kong Drs. C. W. Fung, L.Y. Chong, C.Y. Leung, C. N. Look, K.K. Lo, K. M. Ho Social Hygiene Service
More informationX-Plain Psoriasis Reference Summary
X-Plain Psoriasis Reference Summary Introduction Psoriasis is a long-lasting skin disease that causes the skin to become inflamed. Patches of thick, red skin are covered with silvery scales. It affects
More informationNAI A L I TI T P I S FO F R THE
NAIL TIPS FOR THE PRACTICING DERMATOLOGIST Boni E. Elewski, MD James Elder, MD Endowed Professor of Dermatology University of Alabama Conflict of Interests Clinical Research: Amgen, Abbvie, Lilly, Merck,
More informationD.RIGOPOULOS, D.IOANNIDES,* D.KALOGEROMITROS, S.GREGORIOU AND A.KATSAMBAS
British Journal of Dermatology 24; 151: 171 175. DOI: 1.1111/j.1365-2133.24.628.x Therapeutics Pimecrolimus cream 1% vs. betamethasone 17-valerate Æ1% cream in the treatment of seborrhoeic dermatitis.
More informationProduct: Tazarotene, cream, 500 micrograms per g (0.05%) and 1.0 mg per g (0.1%), 30 g, Zorac
PUBLIC SUMMARY DOCUMENT Product: Tazarotene, cream, 500 micrograms per g (0.05%) and 1.0 mg per g (0.1%), 30 g, Zorac Sponsor: Genepharm Australasia Ltd Date of PBAC Consideration: July 2007 1. Purpose
More informationTOPICAL TREATMENTS FOR PSORIASIS
TOPICAL TREATMENTS FOR PSORIASIS What are the aims of this leaflet? Patients with psoriasis are usually treated with preparations that are applied to the skin. This leaflet has been written to help you
More informationPSORIASIS THE RELATIONSHIP BETWEEN NAIL CHANGES, THE EVOLUTION AND THE CLINICAL FORM OF THE DISEASE
STUDII CLINICE ªI EXPERIMENTALE PSORIASIS THE RELATIONSHIP BETWEEN NAIL CHANGES, THE EVOLUTION AND THE CLINICAL FORM OF THE DISEASE MARIA ROTARU*, FLORINA POPA**, GABRIELA IANCU* Sibiu Summary Psoriatic
More informationPreetha selva et al. / International Journal of Phytopharmacology. 6(1), 2015, 42-46. International Journal of Phytopharmacology
International Journal of Phytopharmacology Journal homepage: www.onlineijp.com 42 e- ISSN 0975 9328 Print ISSN 2229 7472 IJP A CLINICAL STUDY TO EVALUATE THE EFFECT OF TOPICAL TAZAROTENE IN THE TREATMENT
More informationInterventions for nail psoriasis (Review)
de Vries ACQ, Bogaards NA, Hooft L, Velema M, Pasch M, Lebwohl M, Spuls PI This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library
More informationTreatment of Nail Psoriasis Best Practice Recommendations From the Medical Board of the National Psoriasis Foundation
Clinical Review & Education Consensus Statement Best Practice Recommendations From the Medical Board of the National Psoriasis Foundation Jeffrey J. Crowley, MD; Jeffrey M. Weinberg, MD; Jashin J. Wu,
More informationScottish Medicines Consortium
Scottish Medicines Consortium betamethasone valerate 2.25mg medicated plaster (Betesil ) No. (622/10) Genus Pharmaceuticals 09 July 2010 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationNail Psoriasis. A positive approach. to psoriasis and. psoriatic arthritis
Nail Psoriasis A positive approach to psoriasis and psoriatic arthritis What are the aims of this leaflet? This leaflet has been written to help you understand what nail psoriasis is, what changes can
More informationPrescribing advice for the management and treatment of psoriasis
Prescribing advice for the management and treatment of psoriasis This guidance contains suggested advice for the management and treatment of patients presenting with psoriasis. This guidance applies to
More informationHow To Treat Psoriasis With Omega 3 Fatty Acids
CAN PSORIASIS TREATMENT BE AIDED BY OMEGA-3 FATTY ACIDS? Brittney Urban Psoriasis Chronic skin disease Cell life cycle build up Can be disabling Symptoms: Red patches with silvery scales Dry, cracked skin
More informationTNF-α Antagonists in the Treatment of Nail Psoriasis
Review DOI: 10.6003/jtad.1264r1 TNF-α Antagonists in the Treatment of Nail Psoriasis Zekayi Kutlubay, MD, Burhan Engin, MD, Abdullah Songür, MD, Yalçın Tüzün, MD Address: Istanbul University, Cerrahpaşa
More informationPSORIASIS AND ITS. Learn how vitamin D medications play an important role in managing plaque psoriasis
PLAQUE PSORIASIS AND ITS TREATMENTS Learn how vitamin D medications play an important role in managing plaque psoriasis 2 Understanding Plaque Psoriasis WHAT CAUSES PLAQUE PSORIASIS? No one knows exactly
More informationNail Psoriasis. A positive approach. to psoriasis and. psoriatic arthritis
Nail Psoriasis A positive approach to psoriasis and psoriatic arthritis What are the aims of this leaflet? This leaflet has been written to help you understand what nail psoriasis is, what changes can
More information74 Full Text Available On www.ijupls.com. Medical Sciences. Original Article!!!
International Journal of Universal Pharmacy and Life Sciences 2(2): March-April 2012 INTERNATIONAL JOURNAL OF UNIVERSAL PHARMACY AND LIFE SCIENCES Medical Sciences Original Article!!! Received: 18-04-2012;
More informationIs Monotherapy Treatment of Etanercept Effective Against Plaque Psoriasis?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2011 Is Monotherapy Treatment of Etanercept
More informationPATIENT RESOURCES: PSORIASIS
PATIENT RESOURCES: PSORIASIS Psoriasis is a persistent skin disorder in which there are red, thickened areas with silvery scales, most often on the scalp, elbows, knees, and lower back. Some cases, of
More informationComparison of the Effect of Azelaic Acid 20% And Clindamycin 1% In the Treatment of Mild And Moderate Acne. Abstract
Original Article Comparison of the Effect of Azelaic Acid 20% And Clindamycin 1% In the Treatment of Mild And Moderate Acne Soudabeh Tirgar Tabari, MD Ali Akbar Moghadam Nia, PharmD Karimollah Hajian Amirmajid
More informationLaser treatment for toenail fungus
Laser treatment for toenail fungus David M. Harris a,b, Brian A. McDowell c, John Strisower b, a Univ. of Washington, Seattle WA, USA 98195; b PathoLase, Inc. 275 Airpark Blvd., Chico, CA 95973; c Northern
More informationAvailable online www.jocpr.com. Research Article
Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research, 2014, 6(2):736-741 Research Article ISSN : 0975-7384 CODEN(USA) : JCPRC5 A comparative study of efficacy and safety of combination
More informationPsoriasis Co-morbidities: Changing Clinical Practice. Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology. Psoriatic Arthritis
Psoriasis Co-morbidities: Changing Clinical Practice Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology Psoriatic Arthritis Psoriatic Arthritis! 11-31% of patients with psoriasis have psoriatic
More informationPsoriasis Agents, Topical Review 01/18/2010
Review 01/18/2010 Copyright 2007-2010 by Provider Synergies, L.L.C. All rights reserved. Printed in the United States of America. All rights reserved. No part of this publication may be reproduced or transmitted
More informationResults of the first clinical study on a new treatment for Psori asis: the T.M.S.T. method
MINERAL MOR LTD Results of the first clinical study on a new treatment for Psori asis: the TMST method Marco Harari MD 12122012 Conclusions: 1 No side effects were recorded during the 5week study period
More informationLaser Therapy for Plaque Psoriasis
Laser Therapy for Plaque Psoriasis Policy Number: Original Effective Date: MM.02.027 12/01/2015 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 12/01/2015 Section: Medicine Place(s)
More informationPsoriasis: Controlled YOUR GUIDE TO BIOLOGICAL TREATMENTS FOR PLAQUE PSORIASIS
Psoriasis: Controlled YOUR GUIDE TO BIOLOGICAL TREATMENTS FOR PLAQUE PSORIASIS 2 Proudly supported by Disclaimer: Some photographs and models used in this booklet are for illustrative purposes only and
More informationGENETIC ANALYSIS OF PSORIASIS AND PSORIATIC ARTHRITIS Department of Dermatology, University of Michigan
GENETIC ANALYSIS OF PSORIASIS AND PSORIATIC ARTHRITIS Department of Dermatology, University of Michigan SELF ASSESSMENT FORM FOR STUDY SUBJECTS AND CONTROLS Accession Number (will be filled in by lab)
More informationPsoriasis Treatment Transition Pathway
Psoriasis Treatment Transition Pathway A Treatment Support Tool Adapted from Circle Nottingham NHS Treatment Centre Psoriasis Pathway (under consultation) with support from Abbvie Ltd Treatment Pathways
More informationPsoriasis - suspected
Psoriasis - suspected Possible link to alcohol use, depression, other medications History and examination Consider referral to Health Trainers Consider differential diagnoses Is the patient systemically
More informationGuidelines of care for the management of psoriasis and psoriatic arthritis
FROM THE ACADEMY Guidelines of care for the management of psoriasis and psoriatic arthritis Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies Alan Menter,
More informationPsoriasis Can be Cured with Homoeopathy
Homoeopathy Clinic http://www.homoeopathyclinic.com Psoriasis Can be Cured with Homoeopathy Case Report / General Information What you should Know about Psoriasis? It is not a contagious disease. Psoriasis
More informationPsoriatic Arthritis www.arthritis.org.nz
Psoriatic Arthritis www.arthritis.org.nz Did you know? Arthritis affects one in six New Zealanders over the age of 15 years. Psoriatic arthritis usually appears in people between the ages of 30 to 50.
More informationMale New Patient Package
Male New Patient Package The contents of this package are your first step to restore your vitality. Please take time to read this carefully and answer all the questions as completely as possible. Thank
More informationPsoriatic Arthritis. Psoriatic Arthritis 3/05
Psoriatic Arthritis 3/05 Psoriatic Arthritis Arthritis Ireland, 1 Clanwilliam Square, Grand Canal Quay, Dublin 2 T: (01) 661 8188 F: (01) 661 8261 www.arthritisireland.ie What is in this booklet? This
More informationto Part of Dossier: Name of Active Ingredient: Title of Study: Quality of life study with adalimumab in rheumatoid arthritis. ESCALAR.
2.0 Synopsis Abbott Laboratories Name of Study Drug: Individual Study Table Referring to Part of Dossier: Adalimumab (HUMIRA) (For National Authority Use Only) Name of Active Ingredient: Adalimumab Title
More informationMethods of Outcomes Measurement in Nail Psoriasis
Dermatology 2010;221(suppl 1):23 28 DOI: 10.1159/000316177 Published online: August 9, 2010 Methods of Outcomes Measurement in Nail Psoriasis M. Augustin a A. Ogilvie b a Center for Health Services Research
More informationTreatment options a simple guide
Guide Treatment options a simple guide To decide which treatment is right for you, a good starting point is to know what options you have and to understand the pros and cons of each one. People respond
More informationAdditional information >>> HERE <<< How To scalp psoriasis treatment philippines Scam or Work?
Additional information >>> HERE http://urlzz.org/psoriasis7/pdx/fph1
More informationYour psoriasis story. Print this out, answer the questions, then share it with your doctor
Your psoriasis story Print this out, answer the questions, then share it with your doctor 1 SYMPTOMS Surface Area Your doctor will use a variety of different factors to measure the severity of your disease,
More informationBJD British Journal of Dermatology. Summary SYSTEMATIC REVIEW
SYSTEMATIC REVIEW BJD British Journal of Dermatology Topical therapies for the treatment of plaque psoriasis: systematic review and network meta-analyses E.J. Samarasekera, 1 L. Sawyer, 2 D. Wonderling,
More informationSTUDY. Long-term Effectiveness of Treatment With Terbinafine vs Itraconazole in Onychomycosis
STUDY Long-term Effectiveness of Treatment With vs in Onychomycosis A 5-Year Blinded Prospective Follow-up Study Bárður Sigurgeirsson, MD, PhD; Jón H. Ólafsson, MD, PhD; Jón þ. Steinsson, MD Carle Paul,
More informationScience > MultiClear. How the MultiClear works?
Science > MultiClear How the MultiClear works? Treatment of Psoriasis by UVB is a common, effective and respected therapy for more than 100 years.[1] Narrow band UVB light (peak 296-313 nm) has been clinically
More informationOxford University Hospitals. NHS Trust. Dermatology Department Frontal Fibrosing Alopecia. Information for patients
Oxford University Hospitals NHS Trust Dermatology Department Frontal Fibrosing Alopecia Information for patients What is Frontal Fibrosing Alopecia (FFA)? FFA is a condition which causes hair loss, mainly
More informationGP Symposium Dermatology Dr Seow Hoong Foo Dr Shireen Velangi March 6th 2014
Psoriasis : It s not just skin de eep NICE Guidelines and Quality Standards: a collaboration to deliver quality care GP Symposium Dermatology y p gy Dr Seow Hoong Foo Dr Shireen Velangi March 6th 2014
More informationDevelopment and Validation of a Screening Questionnaire for Psoriatic Arthritis
Development and Validation of a Screening Questionnaire for Psoriatic Arthritis Dafna D. Gladman 1, Catherine T. Schentag 1, Brian D. Tom 2, Vinod Chandran 1, Cheryl F. Rosen 1 Vernon T. Farewell 2 1 University
More informationScalp Psoriasis. A positive approach. to psoriasis and. psoriatic arthritis
10672 SCALP0913 Scalp Psoriasis 12pp final_layout 1 11/10/2013 18:13 Page 2 Scalp Psoriasis A positive approach to psoriasis and psoriatic arthritis What are the aims of this leaflet? This leaflet has
More informationA comparison of efficacy and safety of topical 0.1% adapalene and 4% benzoyl peroxide in the treatment of mild to moderate acne vulgaris
Original Article A comparison of efficacy and safety of topical 0.1% adapalene and 4% benzoyl peroxide in the treatment of mild to moderate acne vulgaris Usma Iftikhar, Shahbaz Aman, Muhammad Nadeem, Atif
More informationNeutral Superoxidized solution vs. benzoyl peroxide gel 5% in the treatment of. Superoxidized solution (SOS) is an electrochemically processed aqueous
Neutral Superoxidized solution vs. benzoyl peroxide gel 5% in the treatment of acne vulgaris: a randomized open-label clinical trial. Summary. Superoxidized solution (SOS) is an electrochemically processed
More informationSTOP HAIR LOSS DR JOYCE LIM DERMATOLOGIST PARAGON MEDICAL CENTRE #11-16/20
STOP HAIR LOSS DR JOYCE LIM DERMATOLOGIST PARAGON MEDICAL CENTRE #11-16/20 HAIR LOSS Types of Hair loss What causes them What are the solutions HAIR LOSS PATCHY HAIR LOSS PATCHY HAIR LOSS Single/ Multiple
More informationVITAMIN C AND INFECTIOUS DISEASE: A REVIEW OF THE LITERATURE AND THE RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PROSPECTIVE STUDY OVER 8 YEARS
39 Chapter 3 VITAMIN C AND INFECTIOUS DISEASE: A REVIEW OF THE LITERATURE AND THE RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PROSPECTIVE STUDY OVER 8 YEARS Maxine Briggs TABLE OF CONTENTS I. Review of the
More informationPSORIASIS. -Multi factorial. -Papulosquamous disorder. -Genetically determined (few) -Chronic Scaly lesions. -Seasonal variations
PSORIASIS -Multi factorial -Papulosquamous disorder -Genetically determined (few) -Chronic Scaly lesions -Seasonal variations -Recurrences & remissions Etiology & Pathogenesis T-cell mediated autoimmune
More informationCOMPOUNDING PHARMACY SOLUTIONS PRESCRIPTION COMPOUNDING FOR DERMATOLOGY
JUNE 2012 COMPOUNDING PHARMACY SOLUTIONS PRESCRIPTION COMPOUNDING WWW.CPSRXS. COM We customize individual prescriptions for the specific needs of our patients. INSIDE THIS ISSUE: Acne 2 Cutaneous Candidiasis
More informationPsoriatic arthritis FACTSHEET
1 What is psoriatic arthritis? Psoriatic arthritis (PsA) is a disease where joints around the body become inflamed and sore. It can make moving about difficult and painful. People who have PsA also have
More informationTherapeutics for the Clinician
A Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of 2 Treatments in articipants With Mild to Moderate Acne Vulgaris Zoe Diana Draelos, MD; Alan R. Shalita, MD; Diane Thiboutot, MD;
More informationCAN-FITE BIOPHARMA LTD.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/131638
More informationScalp psoriasis: European consensus on grading and treatment algorithm
DOI: 10.1111/j.1468-3083.2009.03372.x JEADV CONFERENCE REPORT Scalp psoriasis: European consensus on grading and treatment algorithm JP Ortonne,, * S Chimenti, T Luger, L Puig, F Reid,** RM Trüeb Centre
More informationteaching hospital and research centre, Himayath sagar road, Hyderabad, Telangana state, India 2
Scholars Journal of Applied Medical Sciences (SJAMS) Sch. J. App. Med. Sci., 15; 3(A):215-219 Scholars Academic and Scientific Publisher (An International Publisher for Academic and Scientific Resources)
More information2-5 % Europeans A distressing, life-long, inflammatory disease Impairs patients Quality of Life
Psoriasis: 2-5 % Europeans A distressing, life-long, inflammatory disease Impairs patients Quality of Life 15-25%: moderate-to-severe disease - candidates for systemic therapies - often difficult to manage
More informationEfficacy and safety of simvastatin in chronic plaque psoriasis
Original Article Efficacy and safety of simvastatin in chronic plaque psoriasis Shazia Aslam, Khawar Khurshid, Faria Asad, Zahida Rani,Sabrina Suhail Pal Department of Dermatology, Unit II, King Edward
More informationNational Medicines Information Centre ST. JAMES S HOSPITAL DUBLIN 8 TEL 01-4730589 or 1850-727-727 FAX 01-4730596 E-Mail: nmic@stjames.
VOLUME 6 NUMBER 6 2000 PSORIASIS National Medicines Information Centre ST. JAMES S HOSPITAL DUBLIN 8 TEL 01-4730589 or 1850-727-727 FAX 01-4730596 E-Mail: nmic@stjames.ie SUMMARY The aim of treatment is
More informationOriginal Article ABSTRACT INTRODUCTION
Original Article 1 1,5 2, 4 1 Departments of Dermatology, 1 Intermedica Clinic for Hair Diseases, Department of Dermatology, Boxmeer, The Netherlands, 2 Faculty of Medicine, International University of
More informationHelpline No: 0861 30 30 30
ARTHRITIS FOUNDATION Registered Nonprofit Organisation - No. 002-847 NPO Helpline No: 0861 30 30 30 PSORIATIC ARTHRITIS This information leaflet is published by the Arthritis Foundation as part of our
More informationPsoriasis. Psoriasis. Mark A. Bechtel, M.D. Director of Dermatology The Ohio State University College of Medicine
Psoriasis Mark A. Bechtel, M.D. Director of Dermatology The Ohio State University College of Medicine Psoriasis Psoriasis is a chronic skin disorder resulting from a polygenic predisposition combined with
More informationCutaneous Lymphoma FAST FACTS
Cutaneous Lymphoma FAST FACTS What is Cutaneous Lymphoma? Cutaneous lymphomas are types of non-hodgkin s lymphomas (NHL) that originate in the lymphocytes (white blood cells). Unlike most other types of
More informationDepartment of Dermatology, Churchill Hospital PUVA Treatment
Oxford University Hospitals NHS Trust Department of Dermatology, Churchill Hospital PUVA Treatment information for patients CONTENTS What is PUVA 3 What conditions are treated with PUVA? 3 How is PUVA
More informationNew Developments in the Topical Management of Acne
Clinical Review New Developments in the Topical Management of Acne Abstract Adapalene 0.1%/BPO 2.5% (adapalene/bpo) gel is a novel agent for acne therapy that has recently become available in Canada. This
More informationPACT. PACT Nail Fungus Therapy Treatment Instructions. Photodynamic therapy for nail fungus using light, safely and gently.
PACT PACT Nail Fungus Therapy Treatment Instructions Photodynamic therapy for nail fungus using light, safely and gently. PACT Nail Fungus Therapy Treatment Instructions Contents 1. Introduction 2. Nail
More informationPsoriasis. Etiology. Clinical feature. Head to Toe Psoriasis, How to Treat? Precipitating factor 11/19/2012
Psoriasis Head to Toe Psoriasis, How to Treat? Charoen Choonhakarn, MD Division of Dermatology, Faculty of Medicine Khon Kaen University Chronic inflammatory skin disease, 1-2% of population Male = female,
More information1. ACNE 1. Lisa Schmidt, MPH, Eve A. Kerr, MD, and Kenneth Clark, MD
1. ACNE 1 Lisa Schmidt, MPH, Eve A. Kerr, MD, and Kenneth Clark, MD The general approach to summarizing the key literature on acne was to review relevant sections of two medical text books (Vernon and
More informationFor more information, please contact the National Psoriasis Foundation at 800-723-9166 or
For more information, please contact the National Psoriasis Foundation at 800-723-9166 or www.psoriasis.org. PSORIASIS 101: LEARNING TO LIVE IN THE SKIN YOU RE IN is part of an awareness program to educate
More informationAn Assessment of the Cost-Utility of Therapy for Psoriasis
An Assessment of the Cost-Utility of Therapy for Psoriasis The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation Published
More informationSponsor Novartis. Generic Drug Name Secukinumab. Therapeutic Area of Trial Psoriasis. Approved Indication investigational
Clinical Trial Results Database Page 2 Sponsor Novartis Generic Drug Name Secukinumab Therapeutic Area of Trial Psoriasis Approved Indication investigational Clinical Trial Results Database Page 3 Study
More informationFOX 1064 - Laser Therapy ONYCHOMYKOSIS FUNGAL NAIL INFECTION (ONYCHOMYCOSIS) FOX 1064 nm LASER INNOVATION MA DE IN GERMA NY
US? G N U F L I A N N A IL S FOX: CLEAR DICATION WITHOUT ME FOX 1064 - Laser Therapy ONYCHOMYKOSIS FUNGAL NAIL INFECTION (ONYCHOMYCOSIS) FOX 1064 LASER INNOVATION MA DE IN GERMA NY FOX Laser offers an
More informationAnalysis of Factors Influencing Clinical Types of Psoriasis Vulgaris
대 한 건 선 학 회 지 제 5 권, 제 1 호 Journal of the Korean Society for Psoriasis Vol. 5, No. 1, 43-47, 2008 Analysis of Factors Influencing Clinical Types of Psoriasis Vulgaris Sang Eun Lee, M.D., Jung Eun Lee,
More informationD E R M A T O L O G Y
We customize individual prescriptions for the specific needs of our patients. J A N U A R Y 2 0 1 3 I N S I D E T H I S I S S U E : Warts 2 Melasma 3 P R E S C R I P T I O N C O M P O U N D I N G F O R
More informationAdditional information >>> HERE <<< How To scalp psoriasis treatment philippines Scam or Work?
Additional information >>> HERE http://urlzz.org/psoriasis7/pdx/fph1
More informationEvidence-Based Review of Topical Treatments for Psoriasis. Maryann Mikhail and Noah Scheinfeld, MD
DERMATOLOGY Evidence-Based Review of Topical Treatments for Psoriasis Maryann Mikhail and Noah Scheinfeld, MD ABSTRACT PURPOSE: To understand the appearance, clinical variation, epidemiology, and pathophysiology
More informationHLA-Cw*0602 associates with a twofold higher prevalence. of positive streptococcal throat swab at the onset of
1 HLA-Cw*0602 associates with a twofold higher prevalence of positive streptococcal throat swab at the onset of psoriasis: a case control study Lotus Mallbris, MD, PhD, Katarina Wolk, MD, Fabio Sánchez
More informationX-Plain Alopecia Reference Summary
X-Plain Alopecia Reference Summary Introduction Hair loss is very common in both men and women. You or someone you love may be experiencing hair loss. Hair follicle Learning about normal hair growth is
More informationPowerLight LED Light Therapy. The FUTURE of corrective skin
PowerLight LED Light Therapy The FUTURE of corrective skin care TODAY LED facial treatments Effective when used with correct protocols Non thermal stimulation of collagen Increases circulation and lymphatic
More informationA 3-PRODUCT SALICYLIC ACID REGIMEN EFFECTIVELY TREATS ACNE VULGARIS IN POST- ADOLESCENT WOMEN
A 3-PRODUCT SALICYLIC ACID REGIMEN EFFECTIVELY TREATS ACNE VULGARIS IN POST- ADOLESCENT WOMEN J. R. Kaczvinsky 1, C. E. Mack 1, L. L. Griffin 1, J. Li 1, R. A. Rose-Mansfield 1, S. C. Weitz 1, M. J. Marmor
More informationOCCUPATIONAL SKIN DISEASES IN NURSES
International Journal of Occupational Medicine and Environmental Health, 2003; 16(3): 241 247 OCCUPATIONAL SKIN DISEASES IN NURSES RUTA TELKSNIENE 1 and VIDMANTAS JANUSKEVICIUS 2 1 Department of Environmental
More informationPsoriasis, Incidence, Quality of Life, Psoriatic Arthritis, Prevalence
1.0 Abstract Title Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients with Psoriasis Severe or Moderate with Adalimumab Treatment (TOGETHER). Keywords Psoriasis,
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Evaluation of Medicines for Human Use London, 18 November 2004 CHMP/EWP/2454/02 corr COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON CLINICAL INVESTIGATION
More informationSummary of the risk management plan (RMP) for Cerdelga (eliglustat)
EMA/743948/2014 Summary of the risk management plan (RMP) for Cerdelga (eliglustat) This is a summary of the risk management plan (RMP) for Cerdelga, which details the measures to be taken in order to
More information